Delving into the Latest Updates on AlloRx(Vitro Biopharma) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Allogenic UC-MSCs (Vitro Biopharma), Allogenic umbilical cord-derived mesenchymal stem cell therapy (Vitro Biopharma)

Target-

Action-

Mechanism

CIK cells replacements(Cytokine-induced killer cells replacements)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesDigestive System Disorders+ [5]

Active Indication

Amyotrophic Lateral SclerosisAutistic DisorderDiabetes Mellitus+ [6]

Inactive Indication

Idiopathic Pulmonary FibrosisPitt-Hopkins SyndromeScleroderma, Systemic

Originator Organization

Vitro Biopharma, Inc.

Active Organization

Vitro Biopharma, Inc.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Introduction/Objective:Trigeminal Neuralgia (TN) is an extremely painful condition without an established treatment other than symptom-suppressive medications or temporary relief from corticosteroid injections. Mesenchymal Stem Cells (MSCs) have demonstrated the ability to enhance healing and reduce inflammation and pain without side effects. Our objective was to evaluate the safety and efficacy of CT-guided foramen ovale MSC injection in the treatment of TN.Methods:A 48-year-old woman presented with a 22-year history of severe TN. Previous treatments, including microvascular decompression, acupuncture, chiropractic adjustment, and hypnotism had failed. Medications decreased pain, but produced severe bothersome mental clouding. After proper informed consent, the patient elected trigeminal nerve injection in the foramen ovale with AlloRx (vitrobiopharma.com Golden Colorado) umbilical cord-derived Mesenchymal Stem Cells (MSCs). An experienced pain specialist with previous experience using CT guidance with sedation to inject the trigeminal nerve in the foramen ovale with corticosteroids performed the injection using 20 million MSCs. The patient reported no adverse events or complications related to the treatment.Results:At 1 month post-treatment, the patient reported dramatically reduced pain/tingling, and no longer needed medication, which resulted in the resolution of her mental clouding. At 12 months post-treatment, some symptoms recurred, but the patient maintained substantial cognitive improvements and required a reduced dose of medication.Conclusion:We have demonstrated, for the first time, CT-guided MSC injection into the foramen ovale to result in significant improvement in trigeminal neuralgia without side effects.

01 Dec 2020·Journal of Translational MedicineQ2 · MEDICINE

Allogeneic administration of human umbilical cord-derived mesenchymal stem/stromal cells for bronchopulmonary dysplasia: preliminary outcomes in four Vietnamese infants

Q2 · MEDICINE

ArticleOA

Author: Nguyen, Liem Thanh ; Nguyen, Kien T ; Nguyen, Anh T T ; Trinh, Nhung T H ; Hoang, Duc M ; Hoang, Van T ; Bui, Hue T H ; Trieu, Thai T H

AbstractBackgroundBronchopulmonary dysplasia (BPD) is a severe condition in premature infants that compromises lung function and necessitates oxygen support. Despite major improvements in perinatal care minimizing the devastating effects, BPD remains the most frequent complication of extreme preterm birth. Our study reports the safety of the allogeneic administration of umbilical cord-derived mesenchymal stem/stromal cells (allo-UC-MSCs) and the progression of lung development in four infants with established BPD.MethodsUC tissue was collected from a healthy donor, followed by propagation at the Stem Cell Core Facility at Vinmec Research Institute of Stem Cell and Gene Technology. UC-MSC culture was conducted under xeno- and serum-free conditions. Four patients with established BPD were enrolled in this study between May 25, 2018, and December 31, 2018. All four patients received two intravenous doses of allo-UC-MSCs (1 million cells/kg patient body weight (PBW) per dose) with an intervening interval of 7 days. Safety and patient conditions were evaluated during hospitalization and at 7 days and 1, 6 and 12 months postdischarge.ResultsNo intervention-associated severe adverse events or prespecified adverse events were observed in the four patients throughout the study period. At the time of this report, all patients had recovered from BPD and were weaned off of oxygen support. Chest X-rays and CT scans confirmed the progressive reductions in fibrosis.ConclusionsAllo-UC-MSC administration is safe in preterm infants with established BPD.Trial registration This preliminary study was approved by the Vinmec International Hospital Ethics Board (approval number: 88/2019/QĐ-VMEC; retrospectively registered March 12, 2019).

100 Deals associated with AlloRx(Vitro Biopharma)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 3	-	Vitro Biopharma, Inc.	-
Autistic Disorder	Phase 3	-	Vitro Biopharma, Inc.	-
Diabetes Mellitus	Phase 3	-	Vitro Biopharma, Inc.	-
Inflammatory Bowel Diseases	Phase 3	-	Vitro Biopharma, Inc.	-
Osteoarthritis	Phase 3	-	Vitro Biopharma, Inc.	-
Rheumatoid Arthritis	Phase 3	-	Vitro Biopharma, Inc.	-
Crohn Disease	Phase 2	-	Vitro Biopharma, Inc.	-
Pitt-Hopkins Syndrome	Discovery	-	Vitro Biopharma, Inc.	01 Dec 2021
Scleroderma, Systemic	Discovery	Antigua and Barbuda	Vitro Biopharma, Inc.	23 Aug 2021
Multiple Sclerosis	Discovery	Antigua and Barbuda	Vitro Biopharma, Inc.	12 Aug 2021